BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19040611)

  • 1. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.
    Odening KE; Li W; Rutz R; Laufs S; Fruehauf S; Fishelson Z; Kirschfink M
    Clin Exp Immunol; 2009 Feb; 155(2):239-48. PubMed ID: 19040611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
    Savas B; Cole SP; Tsuruo T; Pross HF
    J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.
    Donin N; Jurianz K; Ziporen L; Schultz S; Kirschfink M; Fishelson Z
    Clin Exp Immunol; 2003 Feb; 131(2):254-63. PubMed ID: 12562385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
    Ludwig JA; Szakács G; Martin SE; Chu BF; Cardarelli C; Sauna ZE; Caplen NJ; Fales HM; Ambudkar SV; Weinstein JN; Gottesman MM
    Cancer Res; 2006 May; 66(9):4808-15. PubMed ID: 16651436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
    Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multidrug resistance phenotype confers immunological resistance.
    Weisburg JH; Curcio M; Caron PC; Raghu G; Mechetner EB; Roepe PD; Scheinberg DA
    J Exp Med; 1996 Jun; 183(6):2699-704. PubMed ID: 8676093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance.
    Tijerina M; Fowers KD; Kopecková P; Kopecek J
    Biomaterials; 2000 Nov; 21(21):2203-10. PubMed ID: 10985494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study.
    Ivy SP; Olshefski RS; Taylor BJ; Patel KM; Reaman GH
    Blood; 1996 Jul; 88(1):309-18. PubMed ID: 8704189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
    Zhou SF
    Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
    Loeff FC; van Egmond HME; Nijmeijer BA; Falkenburg JHF; Halkes CJ; Jedema I
    Leuk Lymphoma; 2017 Sep; 58(9):1-14. PubMed ID: 28140725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.
    Fan Y; Liao J; Wang Y; Wang Z; Zheng H; Wang Y
    Clin Exp Immunol; 2023 Mar; 211(1):57-67. PubMed ID: 36571232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
    Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
    Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zhankuic Acids A, B and C from
    Teng YN; Wang YH; Wu TS; Hung HY; Hung CC
    Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31766413
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
    Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
    Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purine nucleoside analog--sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell lines.
    Dačević M; Isaković A; Podolski-Renić A; Isaković AM; Stanković T; Milošević Z; Rakić L; Ruždijić S; Pešić M
    PLoS One; 2013; 8(1):e54044. PubMed ID: 23326571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.